Mannheimer Onkologie Praxis
- Address
- Q5, 14-22, 68161 Mannheim, Germany
Mannheimer Onkologie Praxis - Multiple Myeloma Research Center
Mannheimer Onkologie Praxis is a specialized oncology practice dedicated to advancing the treatment of hematological malignancies through participation in cutting-edge clinical research. The center demonstrates particular expertise in multiple myeloma, focusing on innovative combination therapies and novel treatment protocols for newly diagnosed patients.
- Multiple myeloma induction therapy optimization with immunotherapy combinations
- Minimal residual disease assessment and monitoring strategies
- Long-term maintenance therapy protocols for newly diagnosed multiple myeloma patients
The practice is actively involved in phase III randomized trials evaluating isatuximab-based combination regimens with lenalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma. Their research encompasses both induction treatment strategies aimed at achieving deep remissions measured by minimal residual disease negativity, as well as maintenance therapy approaches designed to extend progression-free survival and improve long-term outcomes for patients with this complex hematological disorder.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 5 therapeutic areas and 15 of 48 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 45 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1University Of Cologne2active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1University Of Cologne5trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Mannheimer Onkologie Praxis
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17 | University Of Cologne | Phase III | Not Recruiting | Feb 2021 | — |
IMP list
lock Showing 1 of 48 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 3 | Unknown | 2016-07-15 | 2024-04-03 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.